President Obama’s Precision Medicine Initiative has some diagnostics industry leaders excited for the future—and for good reason.
Tacked on to the president’s 2016 budget proposal, the initiative includes funding for data sharing, research on genetic causes of cancer, regulation of precision medicine, and development of interoperability standards. Healthcare market research publisher Kalorama Information predicts the $215 million dollars it would set aside for those purposes “could provide a boost to the tissue diagnostics and cell-based diagnostics industry.”
Pathologist Eric Walk, chief medical officer for Ventana Medical Systems, says the initiative could boost translational medicine for cancer patients, sending the fruits of research more quickly into clinical settings.
The Tucson, AZ, company is working with several pharmaceutical companies to develop companion diagnostics. Walk hopes having FDA or the National Cancer Institute involved on a precompetitive basis will help companies align on which companion diagnostic will be the standard before a clinical trial begins.
Thermo Fisher Scientific, based in Waltham, MA, is already doing what the government is proposing, looking at hundreds of alternations in genes from a tiny DNA sample, says Mike Nolan, the company’s vice president and general manager of oncology. Next-generation sequencing could make it easier for pharmaceutical companies to find clinical trial participants who have genetic mutations that might respond to their drugs, he says.
The precision medicine initiative will enable Trovagene Inc. and other companies to decipher what used to be known as “junk DNA,” adds Keith McCormick, vice president of sales for the San Diego company. Trovagene makes blood tests and urine tests to detect cancer-causing genetic mutations.
None of these executives wanted to badmouth the initiative, but some say they wish it would provide more money or a focus on diseases beyond cancer.
“It’s a critical piece of the puzzle, but not the whole puzzle,” says Gavin MacBeath, cofounder of Merrimack Pharmaceuticals.
The Cambridge, MA, company studies growth factors in the cells that surround late-stage tumors to determine how those tumors respond to therapy. It also infiltrates tumors with drug-packed nanoparticles that escape the growths’ leaky blood vessels, passing harmlessly through healthy blood vessels, MacBeath says.
“Precision medicine is a very large, broad term, and the way it’s being written up on the government’s Web site is focusing on one of the aspects of precision medicine, possibly to the neglect of these other aspects,” he adds. “It’s just hard to roll out a big initiative to understand the physical structure of everyone’s tumors. I think it’s natural for the initiative to be written this way.”
McCormick believes funding such a public health initiative would surely advance cancer research and put more researchers to work.
Still, it remains to be seen how Congressional Republicans will respond to the proposal. But in the end, one’s political leanings or business interests should not matter, says Nolan, who adds that he believes the initiative is a positive for the diagnostics industry and for cancer research in general.
“Our number one competitor isn’t some other company—it’s cancer,” he says. “If more can access the technology and make sense of the information it provides, then we’re doing really well against our chief competitor.”
|Keep up on on trends in the medical device and diagnostic industry by attending the MD&M East conference and exposition June 9–11, 2015, in New York City.|
Nancy Crotti is a freelance contributor to MD+DI.
Correction: An earlier version of this article incorrectly stated that Thermo Fisher Scientific is headquartered in Carlsbad, CA. The company is based in Waltham, MA.
[image courtesy of COOLDESIGN/FREEDIGITALPHOTOS.NET]